COVID-19: Implications for Patients With CLL

Download All
Keep abreast of ongoing developments in providing optimal care for patients with CLL during COVID-19 and evolving research into countering COVID-19–associated inflammatory cytokine production! Get expert perspectives on emerging data with focused commentaries, an FAQ module, and a “living” slideset regularly updated to incorporate the most important clinical findings on CLL and COVID-19.
Jeff Sharman, MD
person default
Jacob D. Soumerai, MD


What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?

Jeff Sharman, MD Released: June 16, 2020

With the first 6 months of the COVID-19 pandemic behind us, I share how my management of patients with CLL has evolved based on experience and key data emerging on COVID-19 risk in patients with CLL.

person default Jacob D. Soumerai, MD Released: September 30, 2020
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings